WHO Panel Recommends Emergency Use Listing for Bharat Biotech’s Covaxin

An illustrative photo of a person in a face mask holding up a vial labelled ‘Covaxin’. Photo: PTI

New Delhi: The Technical Advisory Group (TAG), an independent advisory committee of the World Health Organisation (WHO), has recommended emergency-use listing (EUL) status for Bharat Biotech COVID-19 vaccine Covaxin, sources in the know said.

The WHO is in the process of evaluating Covaxin’s clinical trial data pursuant to its maker’s application for an EUL.

The TAG on October 26 had sought “additional clarifications” from the company for Covaxin to conduct a final “risk-benefit assessment” for EUL for the vaccine.

WHO has granted emergency use listing (EUL) to #COVAXIN® (developed by Bharat Biotech), adding to a growing portfolio of vaccines validated by WHO for the prevention of #COVID19. pic.twitter.com/dp2A1knGtT

— World Health Organization (WHO) (@WHO) November 3, 2021

“The Technical Advisory Group of WHO has recommended Emergency Use Listing status for Covaxin,” a source told PTI.

The TAG-EUL is an independent advisory group that provides recommendations to WHO on whether a COVID-19 vaccine can be listed for emergency use under the EUL procedure.

Covaxin has demonstrated 77.8% efficacy against symptomatic COVID-19 caused by the ‘original’ wild strain of the novel coronavirus.

In June, the company said it concluded the final analysis of Covaxin efficacy from phase 3 trials.

Bharat Biotech’s Covaxin and AstraZeneca and Oxford University’s Covishield are the two most used vaccines in India.

PTI

The post WHO Panel Recommends Emergency Use Listing for Bharat Biotech’s Covaxin appeared first on The Wire Science.